
Twice-daily dosing of the oral JAK inhibitor deuruxolitinib nearly tripled response rates over once-daily dosing in severe alopecia areata.
Supplements and Featured Publications
about 26 years ago
Discussionabout 26 years ago
Bibliographyabout 26 years ago
Participating Facultyabout 26 years ago
Introduction: Overactive Bladder - Defining the Diseaseabout 26 years ago
The Prevalence of Overactive Bladderabout 26 years ago
Comorbidities Associated with Overactive Bladderabout 26 years ago
Overactive Bladder Significantly Affects Overall Quality of Lifeabout 26 years ago
Economic Considerations in Overactive Bladder





